MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Editas Medicine Inc

Fermé

SecteurSoins de santé

2.54 -6.62

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.51

Max

2.74

Chiffres clés

By Trading Economics

Revenu

-31M

-76M

Ventes

-26M

4.7M

BPA

-0.92

Marge bénéficiaire

-1,633.491

Employés

246

EBITDA

-28M

-72M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+22.66% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

55M

184M

Ouverture précédente

9.16

Clôture précédente

2.54

Sentiment de l'Actualité

By Acuity

77%

23%

353 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juil. 2025, 23:45 UTC

Acquisitions, Fusions, Rachats

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3 juil. 2025, 23:42 UTC

Market Talk

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 23:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3 juil. 2025, 22:59 UTC

Market Talk

Uranium Market About to Enter Lull -- Market Talk

3 juil. 2025, 22:58 UTC

Market Talk

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3 juil. 2025, 22:47 UTC

Market Talk

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3 juil. 2025, 22:21 UTC

Résultats

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3 juil. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 19:28 UTC

Market Talk

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3 juil. 2025, 18:34 UTC

Market Talk

Gold Has Winning Week, But Down Day -- Market Talk

3 juil. 2025, 18:18 UTC

Market Talk

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3 juil. 2025, 17:27 UTC

Market Talk

U.S. Oil Rig Count Continues to Slide -- Market Talk

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious -2-

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3 juil. 2025, 16:20 UTC

Market Talk

Correction to Health Care Roundup: Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Gold Futures Fall Following Jobs Report -- Market Talk

3 juil. 2025, 15:47 UTC

Résultats

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3 juil. 2025, 15:36 UTC

Résultats
Acquisitions, Fusions, Rachats

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

22.66% hausse

Prévisions sur 12 Mois

Moyen 3.14 USD  22.66%

Haut 4 USD

Bas 1 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

4

Achat

5

Maintien

1

Vente

Score Technique

By Trading Central

1.33 / 1.54Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Neutral Evidence

Long Terme

No Evidence

Sentiment

By Acuity

353 / 375Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.